A Phase 2 Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer.

Trial Profile

A Phase 2 Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs SU 014813 (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned end date changed from 1 Nov 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 02 Aug 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top